Dr. Michael Irizarry, Senior Vice-President, Clinical Research, Eisai, Nutley, NJ, discusses the evidence supporting subcutaneous lecanemab for early Alzheimer disease, including dosing, amyloid clearance, and safety monitoring.
advertisement
Subcutaneous Lecanemab for Early Alzheimer Disease: Evidence, Safety, and Patient Selection
Share
Save
Restart
Resume
Transcript
Subcutaneous Lecanemab for Early Alzheimer Disease: Evidence, Safety, and Patient Selection
closeShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Dr. Michael Irizarry, Senior Vice-President, Clinical Research, Eisai, Nutley, NJ, discusses the evidence supporting subcutaneous lecanemab for early Alzheimer disease, including dosing, amyloid clearance, and safety monitoring.
Title
Program Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?